Connect with us

Featured

Epazz, Inc (OTCMKTS: EPAZ) Stock Surges After a Recent Series of Important Developments

Published

on

Epazz, Inc (OTCMKTS: EPAZ) recently started seeing significant stock price improvements after ten months of drops that left the value of its shares. The company has seen fairly rough performance in the last 15 months, with its stock price heading from $0.026 in January 2022 to $0.0028 in January 2023, after a full year of spiraling down. The stock did have an occasional interruptive surge, but they were never very long or particularly strong. However, the arrival of 2023 changed this — not immediately, as the price did see some stability throughout January and the first half of February, fluctuating between $0.003 and $0.004 during this period.

To Find out the inside Scoop on EPAZ, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

However, as of February 14th, EPAZ started seeing strong upward movements that broke several major resistances, finding itself at the price of 0.0118 for the first time since April 2022. Of course, 11 months ago, the price was still spiraling down. This time, it is going in the opposite direction, seeing a strong surge. As mentioned, the rapid bull run started on February 14th, when the EPAZ price skyrocketed from $0.003 to $0.0106 in around six hours, representing one of the sharpest increases that the company has ever seen.

As every overly sharp bull run, it, of course, led to a correction once the price surge lost its momentum, and EPAZ dropped back down to $0.005 on February 17th, only to bounce back up to $0.0076 by February 27th. At the start of March, the price saw another dip to $0.005, but the support at this level once again allowed it to bounce back up, which led it to the current level of $0.0118 on Wednesday, March 8th.

The sudden change in behavior of the EPAZ stock can be attributed to a series of moves that resulted in very positive news for the company. One of the most notable announcements that the company made in the year so far was published on February 8th — merely six days before the first massive spike-up took place. The announcement revealed that the Epazz metaverse On-Site Remote Assist product will expand into Europe, with the company focusing on the German market, as its technology resulted from a research project in Berlin. By combining the company’s metaverse technology with the On-Site Remote Assist product, the firm will be able to allow remote field workers, maintenance and repair crews, and even inspections and monitoring teams to conduct on-site video calls, and communicate with machine experts, create real-time quality assessments, live training, reports, and more.

Following this, about a week after the February 14th spike, reports emerged stating that Epaz Holdings’ ZenaDrone AI Predictive will submit for SBIR with US Government. The company itself announced that it submitted over 5 Phase 1 proposals under the SBIT Phase 1 program, which allows small businesses with innovative products to fast-track US government contracts within 90 days from the moment of submission. In other words, it was speculated that if ZenaDrone receives a Phase 1 contract — up to $75,000 per proposal — the firm would be able to proceed further and submit for a Phase 2 contract, where it would get up to $1.2 million per contract.

At the time, CEO Shaun Passley, Ph.D., said:

We are working towards our first government contract using multiple avenues which will hopefully lead to our first set Government customers and through The SBIR would open us up to the whole federal government to our drone technology.

Lastly, on March 7th, the company also announced that it received official issuance of a Utility Patent from the US Patent Office for its AI-Predictive Smart Charging Pad for ZenaDrone 1000. The firm noted that the Smart Charging Pad would be a major game changer and available at a much lower price than competitors. In comparison, competitors who offer similar charging pads for drones weighing less than 55 pounds charge anywhere from $4,000 to $15,000 per unit. Meanwhile, ZenaDrone 1000 charging pad would be priced at less than $15,000 for a drone that weighs over 250 pounds.

The drone itself is a serious aircraft created for military use, but also for oil, gas, and even agriculture industries.

As for Epazz, Inc., it is a mission-critical provider of various emerging technologies, including metaverse solutions, cryptocurrency apps, blockchain, cloud-based business solutions, and more. It also provides customized software enterprise solutions to governments, businesses, healthcare providers, and others. The company’s ZenaDrone 1000 is another highly important product that was even recognized by the US Air Force, which recently invited ZenaDrone AI Predictive to one of its bases in California for a demonstration of the drone.

For more on EPAZ Subscribe Right Now!

Epazz, Inc. saw a rough year in 2022, like many other technology-oriented companies. However, with the recovering market, its stock price has started down the path of rapid increase, as it reached the bottom which left it heavily undervalued. Especially in the context of recent developments, the quality and innovative nature of its products, and the firm’s ambitions and goals, it feels safe to say that Epazz, Inc. is a company that has massive potential in the future of modern technology. We will be updating on EPAZ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with EPAZ.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in EPAZ, either long or short, and we have not been compensated for this article

Image by Joe from Pixabay

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

IceCure Medical’s (NASDAQ: ICCM) ProSense: A 96.8% Success Rate Revolutionizing Breast Cancer Treatment

Published

on

On October 2nd, 2023, IceCure Medical (NASDAQ: ICCM) shares surged by over 50% following exciting news presented at a major medical event, the European Society of Breast Imaging. Their cutting-edge ProSense® System, designed for minimally invasive cryoablation, is marketed and sold worldwide for its cleared indications in the U.S., Europe, and China. More recently they gained approvals in India, and Brazil and have additional distribution through MC Medical to continue expanding in Europe. More importantly, the latest independent study confirms that the technology is a safe & effective outpatient procedure for breast cancer, with 96.8% success rate.

More Background:

Their system has the potential to revolutionize cancer treatment not only for breast cancer, but also for kidney, bone, and lung cancers. To date, the system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.

During the event, Dr. Lucía Graña-López, a radiologist specializing in breast and women’s imaging, led an independent study. The study explored cryoablation as a viable alternative to surgery for early-stage breast cancer in patients who preferred a non-surgical route. The results were promising, suggesting that cryoablation could be a successful treatment option, particularly for patients hesitant about traditional surgery.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Clinical Study:

The study involved 31 patients with early-stage breast cancer who opted out of surgery, and the outcomes showed that cryoablation was well-tolerated with no major complications. This alternative approach could potentially be a game-changer, especially for breast cancer, which is one of the most prevalent cancers globally. Many patients, particularly older individuals, are seeking less invasive alternatives to surgery, making cryoablation an appealing option.

Dr. Graña-López envisions cryoablation becoming a significant alternative to surgery, particularly for early-stage breast cancer in post-menopausal women. Moreover she believes this technology could reshape how we approach treatment in other indications, particularly for kidney, lung, and thyroid gland cancers.

These results from this independent study are are in line with the ongoing ICE3 study, the largest of its kind in the U.S., set to conclude in early 2024.

We will update you on ICCM when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by marijana1 from Pixabay

Continue Reading

Featured

T2 Biosystems (NASDAQ: TTOO) Breaks Ground: FDA Clearance, Market Trends, and Healthcare Impact

Published

on

Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.

Spotting Biothreats Faster:

T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.

Big Investor Sells:

Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

New CDC Guidelines:

Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.

Buying opportunity of the year!!! Update
byu/den1183 inTTOOstock

T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.

This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.

What Borrowing Costs Tell Us:

Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.

Better News for Patients:

But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care.  They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.

Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.

Conclusion:

T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.

We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Picture by jarmoluk from Pixabay

 

Continue Reading

BioPharma

Organogenesis (NASDAQ: ORGO): Latest Developments and Future Growth Prospects

Published

on

Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).

More Background:

Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.

Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.

He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.

We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by Parentingupstream from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.